Skip to main content

Table 1 The characteristics of the 23 eligible studies

From: Roles of ARID1A variations in colorectal cancer: a collaborative review

Author and country Publication year Type of CRC ARID1A variation (%) ARID1A expression Roles of ARID1A Clinicopathologic features or biological effects of ARID1A Antibodies of ARID1A References
Jones, USA 2012 CRC 12/119, 10% Downregulated Suppressor ARID1A inactivation promoted CRC development NA Jones et al. (2012)
Chou, Australia 2014 CRC 110/1876, 5.9%; Loss of expression Suppressor No significant relationship between loss expression of ARID1A and the OS of CRC; Loss expression of ARID1A was associated with multiple clinical features, BRAFV600E variation and loss of mismatch repair protein expression (all P < 0.01) Sigma 1: 100 Chou et al. (2014)
Cajuso, Finland 2014 CRC 18/46, 39% Downregulated Suppressor Exome sequencing showed that ARID1A play an important role in microsatellite-unstable CRC via DNA binding activity and transcription coactivator activity Santa Clara Cajuso et al. (2014)
Xie, China 2014 CRC 26/86, 30.2% Loss of expression Suppressor Loss of ARID1A significantly associated with poor differentiation of CRC (P = 0.0009) Rabbit antibodies Sigma 1:500 Xie et al. (2014)
Ye, USA 2014 CRC 22/257, 9% Loss of expression Suppressor ARID1A loss was significantly associated with various clinicopathological features of CRC (all P < 0.05), and with a trend toward a worse OS (P > 0.05) polyclonal antibody Sigma- 1:100 Ye et al. (2014)
Wei, China 2014 CRC 54/209, 25.8% Loss of expression Suppressor ARID1A loss was correlated to late TNM stage, distant metastasis, and poor pathological classification (all P < 0.05) Santa Cruz Biotechnology Wei et al. (2014)
Lee, Korea 2015 CRC 12/196, 6.1% Loss of expression Suppressor Loss of ARID1A expression was significantly correlated with negative lymphatic invasion (P = 0.003) in CRC, and with expanding tumor border (CRC, P = 0.010) Rabbit polyclonal, Sigma 1:100 Lee et al. (2015)
Lee, USA 2016 CRC 49/552, 8.9% Loss of expression Suppressor ARID1A loss was associated with mismatch-repair protein deficiency. poor differentiation, lymphovascular invasion, and higher pT stage (all P < 0.05) Rabbit polyclonal, Sigma, 1:300 Lee et al. (2016)
Agaimy, Germany 2016 Colon, small bowel, and stomach cancer 2/13, 15.4% Loss of expression Suppressor NA Rabbit polyclonal Abcam, 1:100 Agaimy et al. (2016)
Fountzilas, USA 2018 CRC 16/36, 44% Loss of expression Suppressor ARID1A variations independently predicted for unfavorable DFS (HR = 1.99, 95%CI 1.11–3.54, P = 0.020) NA Fountzilas et al. (2018)
Wan, China 2018 CRC 3/16, 18.8% Loss of expression Suppressor NA MygeneSeq technology Wan et al. (2018)
Sen, USA 2019 CRC 24/164, 14.6% Loss of expression Suppressor The expression of ARID1A plays a key role in KRAS-mutated CRC cells Cell Signaling, 1:500 Sen et al. (2019)
Kishida, Japan 2019 CRC 10/218, 4.6% Loss of expression Suppressor Loss expression of ARID1A was significantly correlated to younger age, lymphatic invasion, and lymph node metastasis Rabbit monoclonal, 1:500 Kishida et al. (2019)
Xu, China 2020 sCRC 1/28, 3.6% Frameshift variation Suppressor ARID1A variations and the deficiency of its protein expression were significantly involved in advanced tumor depth, poor differentiation, lymphatic metastasis, BRAF V600E variation, MMR deficiency and MSI phenotype in tumors of CRC patients NA Xu et al. (2020)
Tokunaga-1,USA 2020 CRC 468/5726, 8% Downregulated Suppressor ARID1A variations could regulate DNA repair pathways NA Tokunaga et al. (2020)
Tokunaga-2,USA 2020 CRC 50/619, 8% Downregulated Suppressor ARID1A variation was significantly associated with a favourable immune profile indicative of a higher likelihood of response to immune checkpoint inhibitors NA Tokunaga et al. (2020)
Tokunaga-3,USA 2020 CRC 104/1099, 10% Downregulated Suppressor ARID1A variation was associated with right-sided primary tumor location and earlier tumor stage NA Tokunaga et al. (2020)
Tokunaga-4,USA 2020 CRC 58/534, 11% Downregulated Suppressor ARID1A variations lead to strong immune activation in CRC NA (Tokunaga et al. 2020)
Erfani, Iran 2020 CRC 12/18, 66.7% Loss or low expression Suppressor No significant relationship was found between the loss of ARID1A and the OS or the clinicopathological features in CRC Rabbit antibody Sigma 1:200 Erfani et al. (2020)
Villatoro, USA 2020 Colorectal adenocarcinoma 16/338, 4.7%; Deficiency Suppressor No difference in disease-specific or disease-free survival was found for ARID1A deficiency (all P > 0.05) Abcam Villatoro et al. (2020)
Stein, USA 2020 pCRC PM pCRC: 179/617, 29%, PM: 42/348, 12% Variation Suppressor NA Primary antibody clones Stein et al. (2020)
Wang-1, China 2020 CRC 76/156, 48.7% Downregulated Suppressor NA NA Wang et al. (2020)
Wang-2, China 2020 CRC 17/225, 7.6% Downregulated Suppressor NA NA Wang et al. (2020)
Jiang, China 2020 CRC 89/1234, 7.2% Variation Suppressor CRC patients with ARID1A variation showed a significantly longer DFS/PFS (HR = 0.74, P = 0.0026) NA Jiang et al. (2020)
Huang, China 2021 CRC 65/630, 10.3% Variation Suppressor NA NA (Huang et al. 2021)
Perna, Spain 2021 HG-CRCs 12/29, 41.4% Loss of expression Suppressor The differences in survival were not statistically significant (HR = 0.58, 95% CI = 0.23–1.49, P = 0.257) Polyclonal Sigma, 1:500 Perna et al. (2021)
Kamori, Japan 2021 CRC 20/201, 10% Variation Suppressor Tumor histological grade was significantly correlated with ARID1A variation status in those patients with right-sided CRC Rabbit polyclonal, Kamori et al. (2021)
  1. ARID1A AT-rich interactive domain 1A, CRC colorectal cancer, HR Hazard ratio, OR odds ratio, OS overall survival, DFS disease-free survival, HG-CRC high grade colorectal carcinomas, RCC right-sided colorectal cancer, LCC left-sided colorectal cancer, pCRC primary colorectal cancer, NA not available, PFS progression-free survival, RFS recurrence-free survival